FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2365-2367 November 30, 2006 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Campbell, E. G. Related Article by Hampson, L. A. PubMed Citation

Whenever conflict of interest is mentioned in the context of clinical research, we tend to think of financial interests that may influence the ability of a person — particularly, a member of an institutional review board (IRB) — to make impartial decisions about the risks and benefits of a protocol. However, other interests are equally important elements of the clinical research enterprise. Research volunteers are vitally interested in their personal health, industry is strongly motivated to develop new diagnostics and therapeutics, and government entities are pledged to ensure proper oversight and conduct of research involving human subjects. Above all, maintaining . . . [Full Text of this Article]

Source Information

From the National Heart, Lung, and Blood Institute, Bethesda, MD.

This article has been cited by other articles:

• Loscalzo, J. (2007). Entrepreneurship in the Medical Academy: Possibilities and Challenges in Commercialization of Research Discoveries. Circulation 115: 1504-1507 [Full Text]